Haichen Pharmaceutical (300584.SZ): APIs for some products are actively exploring new processes, including using biofermentation to replace traditional chemical synthesis processes

Gelonghui May 9 丨 Some investors asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does the company have synthetic biotechnology-related technology reserves?” The company replied that the APIs for some of the company's products are actively exploring new processes, including using biological fermentation to replace traditional chemical synthesis processes to further reduce production costs and increase profit margins.

Gelonghui FinanceMay 9 04:06 ET

Haichen Pharmaceutical (300584.SZ) announced its 2023 annual results, with net profit of 363.15,600 yuan, an increase of 11.92% year-on-year

According to Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 518 million yuan, a year-on-year decrease of 1.64%; net profit attributable to shareholders of listed companies was 363.15,600 yuan, an increase of 11.92% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 369.653 million yuan, an increase of 17.51% over the previous year; the company plans to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.

Zhitong FinanceApr 24 06:11 ET

Liu Xiaoquan, the majority shareholder of Haichen Pharmaceutical (300584.SZ), plans to reduce holdings by no more than 1.082,700 shares

Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the company's shareholder holding more than 5% of the shares, plans to focus on bidding and big...

Zhitong FinanceApr 18 06:54 ET

Liu Xiaoquan, the main shareholder of Haichen Pharmaceutical (300584.SZ), reduced its shares by 1%

Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the shareholder holding more than 5% of the company's shares, reduced the company's shares by 1...

Zhitong FinanceApr 11 09:20 ET

Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Those holding Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) shares would be relieved that the share price has rebounded 26% in the last thirty days, but it needs to keep going to repair the rec

Simply Wall StMar 18 18:14 ET

Haichen Pharmaceutical (300584.SZ): Products suitable for mycoplasma pneumonia are mainly injectable azithromycin

Gelonghui March 6 丨 An investor asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does your company have drugs for mycoplasma pneumonia?” The company replied that the company's products for mycoplasma pneumonia are mainly injectable azithromycin.

Gelonghui FinanceMar 6 03:15 ET